According to Celgene's market research, 15% of MDS patients are treated with either Revlimid or Vidaza.

FORBES: Celgene's Smart Buy

Half the patients taking Vidaza were alive at the end of two years, compared to 26% of those who received the standard therapy.

FORBES: Magazine Article

Pharmion's most successful drug, Vidaza, is also approved to treat MDS, but it is used in a far more severe form of the disease.

FORBES: Magazine Article

"Vidaza has a chance to be a blockbuster, " says Barer.

FORBES: Magazine Article

In results from a late-stage trial released in August, Vidaza was shown to have increased the survival of patients with a high-risk type of MDS from 15 months to 24 months.

FORBES: Magazine Article